- Home
- ACP vs PSNL Comparison
ACP vs PSNL Comparison
Compare ACP & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACP | PSNL |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.9M | 729.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ACP | PSNL |
|---|---|---|
| Price | $5.24 | $6.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 535.3K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 17.79% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $16.94 |
| Revenue Next Year | N/A | $36.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.92 | $2.83 |
| 52 Week High | $6.05 | $11.50 |
Technical Indicators
Market Signals| Indicator | ACP | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 28.69 | 34.61 |
| Support Level | $5.13 | $4.31 |
| Resistance Level | $5.89 | $6.94 |
| Average True Range (ATR) | 0.07 | 0.71 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 3.75 | 5.95 |
Price Performance
Historical ComparisonAbout ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.